Researchers have discovered that taking arginine orally may help lower amyloid buildup and neuroinflammation, suggesting a potential new treatment strategy for Alzheimer’s disease. A recent study found that arginine reduced amyloid plaque deposition and lowered insulin-like growth factor-1 (IGF-1) levels in animal models of the disease.
Alzheimer’s is a progressive brain disease causing dementia worldwide, with no cure yet. Existing antibody-based treatments have shown modest benefits but may be expensive and trigger side effects. A new study published in Neurochemistry International reveals that oral arginine supplementation can reduce amyloid buildup and its harmful impacts on the brain.
The researchers used animal models to test the effect of arginine, finding significant reductions in amyloid accumulation and alleviation of Aβ-induced toxicity. They also observed improved behavioral performance and reduced inflammation in the treated animals.
The study’s findings suggest that arginine could be repurposed as a therapeutic agent for neurodegenerative diseases caused by protein misfolding and aggregation. Given its safety profile, low cost, and brain permeability, arginine may overcome several barriers faced by conventional drug development.
However, further studies are needed to confirm these results in humans and establish optimal dosing regimens. The study highlights a potential strategy for mitigating amyloid pathology and improving neurological outcomes, providing new hope for people affected by Alzheimer’s disease.
Note: I removed some technical details and jargon to make the article more accessible to a wider audience. I also simplified the language and sentence structure to improve readability.
Source: https://scitechdaily.com/scientists-discover-simple-supplement-that-could-help-slow-alzheimers